Eugia US LLC Initiates Nationwide Recall of Progesterone Injection Dueings to Particulate Matter
Eugia US LLC has initiated a Class II nationwide recall of 17,300 vials of Progesterone Injection USP due to particulate matter, specifically a glass piece. This event highlights critical quality control vulnerabilities in the sterile injectable supply chain, particularly for products manufactured internationally. Procurement and regulatory teams must assess immediate supply risks and reinforce supplier qualification protocols for Progesterone.
FDA Class II Recall: Particulate Matter in Eugia US LLC's Progesterone Injection
Eugia US LLC has initiated a voluntary, firm-initiated Class II recall, designated D-0186-2025, for its Progesterone Injection USP, 500mg per 10 mL (50mg/mL), 10 mL Multiple Dose Vials. This critical action stems from a market complaint detailing the presence of a glass piece within a vial, indicating a significant failure in quality control regarding particulate matter. The affected product, identified by NDC # 55150-306-10 and Batch # 1PR24010 with an expiry of February 28, 2027, was distributed nationwide across the USA. A total of 17,300 vials are subject to this recall, representing a substantial volume of a widely used generic hormone therapy. For procurement directors, this event necessitates an immediate review of current inventory and supply agreements for Progesterone Injection. The Class II classification indicates that the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The presence of glass particulates in an injectable product poses a direct risk of vascular occlusion, tissue damage, or other serious patient safety concerns. Regulatory affairs heads must evaluate the implications for product quality specifications and supplier oversight, especially for sterile injectables where particulate control is paramount. Business development executives should note the potential for market disruption and assess opportunities for alternative, compliant suppliers to fill any emerging supply gaps.
Manufacturing Origin and Global Supply Chain Vulnerabilities for Progesterone
The recalled Progesterone Injection USP, while distributed by Eugia US LLC from East Windsor, NJ, is explicitly stated to be manufactured in India. This detail is crucial for supply chain VPs and procurement teams, as it highlights the inherent complexities and potential vulnerabilities associated with international pharmaceutical manufacturing. The reliance on overseas facilities for critical generic medications like Progesterone necessitates rigorous oversight and robust quality agreements that extend beyond the US-based recalling firm to the actual manufacturing site. For companies sourcing active pharmaceutical ingredients (APIs) or finished dosage forms from India, this incident underscores the imperative for enhanced supplier qualification processes and ongoing audit programs. The challenge lies in maintaining consistent quality control across diverse regulatory environments and manufacturing standards. Regulatory affairs teams must ensure that their due diligence for foreign manufacturing partners is comprehensive, covering not only facility inspections but also the entire quality management system, particularly for sterile products where contamination risks are higher. This event serves as a stark reminder that a recall initiated by a US entity can often trace its root cause to manufacturing deficiencies in a foreign facility, impacting the continuity and safety of the US drug supply.
Market Impact and Broader Regulatory Scrutiny on Progesterone Injections
The recall of 17,300 vials of Progesterone Injection USP by Eugia US LLC could create localized supply disruptions, particularly given the nationwide distribution pattern. Progesterone is a critical hormone used in various therapeutic areas, including reproductive health and hormone replacement therapy. Any interruption in its availability can have significant clinical implications for patients and healthcare providers. Procurement directors should assess their current stock levels and the lead times required to secure alternative supplies, considering the potential for increased demand on other manufacturers. This incident is not isolated within the Progesterone market. A parallel event in June 2026 saw Essential Wellness Pharma's Progesterone Injection also face an FDA Class II recall due to sterility assurance failures. This pattern suggests a heightened regulatory focus or potential systemic quality challenges within the manufacturing sector for Progesterone injectable products. Regulatory affairs heads must recognize this trend and anticipate increased FDA scrutiny on all manufacturers of Progesterone injections, demanding more stringent quality control measures and robust sterility assurance programs. Business development executives should view this as an indicator of market volatility, prompting a re-evaluation of product portfolios and potential partnerships with manufacturers demonstrating superior quality and compliance records.
Mitigating Supply Risk: Strategic Sourcing for Sterile Injectable Progesterone
In light of the Eugia US LLC recall, procurement directors must proactively develop and implement robust alternative sourcing strategies for Progesterone Injection. While specific alternative suppliers are not named in the available intelligence, the market for generic Progesterone is typically competitive. Companies should immediately initiate or accelerate the qualification of secondary and tertiary suppliers to diversify their supply base. Key considerations for identifying new partners include their manufacturing site's regulatory history, particularly concerning sterile injectables, and their track record for particulate matter control. Geographic diversification of manufacturing sites is also a critical strategy to mitigate risks associated with regional regulatory issues or supply chain disruptions. This involves looking beyond traditional sourcing hubs to facilities in different countries with strong regulatory oversight. Qualification timelines for new sterile injectable suppliers can be extensive, often spanning 12-24 months due to stringent regulatory requirements for facility audits, analytical testing, and stability studies. Therefore, early engagement is paramount. Supply chain VPs should prioritize investments in supplier relationship management and quality assurance teams to ensure continuous monitoring and auditing of all manufacturing partners, especially those producing high-risk sterile products like Progesterone Injection.
Eugia US LLC's Regulatory Posture and Future Compliance Imperatives
While specific prior regulatory actions against Eugia US LLC are not detailed in the available intelligence, this Class II recall for particulate matter represents a significant event that will undoubtedly elevate the company's profile within the FDA's enforcement framework. The FDA will expect a comprehensive and timely response from Eugia US LLC, including a thorough root cause analysis for the presence of glass particulates and the implementation of robust corrective and preventive actions (CAPA). This will likely involve a detailed investigation into the manufacturing processes at the Indian facility where the product was produced. Regulatory affairs heads at Eugia US LLC must prepare for potential follow-up inspections, which could extend to the manufacturing site in India. Failure to adequately address the identified quality deficiencies could lead to more severe regulatory actions, including a Warning Letter, an Import Alert for products from the implicated facility, or even product seizure. For business development executives, this recall poses a reputational risk that could impact future partnerships and market access. Demonstrating a clear commitment to quality and compliance, backed by verifiable improvements in manufacturing processes, will be critical for Eugia US LLC to regain full market confidence and ensure long-term operational stability.
Remediation and Enhanced Quality Standards for Sterile Injectable Manufacturing
The immediate remediation for Eugia US LLC involves retrieving all affected Progesterone Injection USP vials from the market and conducting a thorough investigation into the root cause of the glass particulate contamination. This process must extend to the manufacturing facility in India to identify and rectify systemic deficiencies in their quality management system, particularly those related to sterile filling and visual inspection processes. The FDA will require detailed documentation of these actions, including evidence of effectiveness and prevention of recurrence. For the broader industry, this recall reinforces the critical importance of robust quality control and assurance programs for all sterile injectable products. Supply chain VPs should review their internal quality standards and audit protocols, ensuring they align with or exceed current good manufacturing practices (cGMP) for parenteral drugs. This includes investing in advanced inspection technologies, implementing comprehensive personnel training on particulate matter detection, and establishing stringent environmental monitoring programs. The focus on injectables, especially high-volume generics like Progesterone, will remain intense, demanding proactive measures from all manufacturers to uphold patient safety and product integrity.